- Home
- DARE vs RADX Comparison
DARE vs RADX Comparison
Compare DARE & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- RADX
- Stock Information
- Founded
- DARE 2015
- RADX 2021
- Country
- DARE United States
- RADX Australia
- Employees
- DARE N/A
- RADX N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- RADX
- Sector
- DARE Health Care
- RADX
- Exchange
- DARE Nasdaq
- RADX NYSE
- Market Cap
- DARE 26.3M
- RADX 32.5M
- IPO Year
- DARE N/A
- RADX N/A
- Fundamental
- Price
- DARE $2.39
- RADX $4.64
- Analyst Decision
- DARE Strong Buy
- RADX Strong Buy
- Analyst Count
- DARE 3
- RADX 3
- Target Price
- DARE $12.50
- RADX $15.00
- AVG Volume (30 Days)
- DARE 4.6M
- RADX 18.6K
- Earning Date
- DARE 08-11-2025
- RADX 02-26-2025
- Dividend Yield
- DARE N/A
- RADX N/A
- EPS Growth
- DARE N/A
- RADX N/A
- EPS
- DARE N/A
- RADX N/A
- Revenue
- DARE $25,909.00
- RADX $204,609.00
- Revenue This Year
- DARE $74,787.57
- RADX N/A
- Revenue Next Year
- DARE $141.76
- RADX N/A
- P/E Ratio
- DARE N/A
- RADX N/A
- Revenue Growth
- DARE N/A
- RADX N/A
- 52 Week Low
- DARE $2.11
- RADX $3.50
- 52 Week High
- DARE $9.19
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- DARE 43.58
- RADX N/A
- Support Level
- DARE $2.44
- RADX N/A
- Resistance Level
- DARE $2.80
- RADX N/A
- Average True Range (ATR)
- DARE 0.66
- RADX 0.00
- MACD
- DARE 0.01
- RADX 0.00
- Stochastic Oscillator
- DARE 5.23
- RADX 0.00
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.